SCHEMBL2016391

SCHEMBL2016391

CCCCc1cccc([N+](=O)[O-])c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.56
ALOX5 P09917 1/20 0.46
PTGS2 P35354 1/20 0.46
ERN1 O75460 1/20 0.46
IAPP P10997 1/20 0.44
TDP1 Q9NUW8 2/20 0.43
ELANE P08246 1/20 0.43
CTSG P08311 1/20 0.43
ALDH1A1 P00352 2/20 0.42
TSHR P16473 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41
BID P55957 3/20 0.41
MCL1 Q07820 3/20 0.41
BCL2L1 Q07817 2/20 0.41
BAK1 Q16611 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8402772 0.94 GPR35 (0.53) GPR35ALOX5PTGS2ERN1ELANE
SCHEMBL5595098 0.90 GPR35 (0.60) GPR35ERN1IAPPTDP1ALDH1A1
SCHEMBL6233468 0.85 ALDH1A1 (0.46) GPR35TDP1ELANECTSGALDH1A1
SCHEMBL30543045 0.84 ALDH1A1 (0.58) ALDH1A1TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL6679612 0.84 ALDH1A1 (0.58) ALDH1A1TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL4854222 0.84 GPR35 (0.67) GPR35ERN1TDP1ALDH1A1TSHR
SCHEMBL30543046 0.84 ALDH1A1 (0.58) ALDH1A1TSHRCYP1A2CYP3A4CYP2C9
Ammonia Solution, Strong SCHEMBL8748291 0.83 ALDH1A1 (0.56) ALDH1A1TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL27973507 0.83 TSHR (0.45) GPR35ALDH1A1TSHRCYP1A2CYP3A4
SCHEMBL27648916 0.83 GPR35 (0.55) GPR35ERN1TDP1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018183367-A1 METHODS OF TREATING CYSTIC FIBROSIS IN PATIENTS WITH RESIDUAL FUNCTION MUTATIONS VAN GOOR FREDRICK F (US) 2018-10-04 WO disclosed
CN-104788328-A Modulators of ATP-binding cassette transporters VERTEX PHARMA 2015-07-22 CN disclosed
CN-101891680-B Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-10-29 CN disclosed
CN-102448952-B Antiviral compounds and uses thereof ABBVIE (US) 2014-10-29 CN disclosed
CN-103641765-A Modulators of ATP-binding cassette transporters VERTEX PHARMA 2014-03-19 CN disclosed
CN-101935301-B Modulators of ATP-binding cassette transporters VERTEX PHARMA 2013-10-16 CN disclosed
EP-2522659-A2 Modulators of ATP-binding cassette transporters Vertex Pharmaceuticals Incorporated (US) 2012-11-14 EP disclosed
EP-2509954-A1 4 -OXO- 1H -QUINOLINE- 3 - CARBOXAMIDES AS MODULATORS OF ATP -BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2012-10-17 EP disclosed
CN-102652128-A 4-Oxo-1H-quinoline-3-carboxamides as modulators of ATP-binding cassette transporters VERTEX PHARMA 2012-08-29 CN disclosed
CN-102448952-A Antiviral compounds and uses thereof ABBOTT LAB 2012-05-09 CN disclosed
WO-2011072241-A1 4 -OXO- IH -QUINOLINE- 3 - CARBOXAMIDES AS MODULATORS OF ATP -BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-16 WO disclosed
CN-101006076-B Modulators of ATP-binding cassette transporters VERTEX PHARMA 2010-09-29 CN disclosed
CN-101006076-A Modulators of ATP-binding cassette transporters VERTEX PHARMA (US) 2007-07-25 CN disclosed
EP-1381590-B1 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS SCHERING CORP (US) 2007-06-20 EP disclosed
CN-1511830-A Compound used as antiphlogistic ���ָ��.Ӣ��ķҩ�﹫˾ 2004-07-14 CN disclosed
CN-1156452-C Compounds as anti-inflammatory agents ���ָ����Ӣ��ķҩ�﹫˾ 2004-07-07 CN disclosed
CN-1349509-A Compounds as anti-inflammatory agents BOEHRINGER INGELHEIM PHARMA (US) 2002-05-15 CN disclosed